Immunovant, Inc. (IMVT)

Immunovant Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	-505.61	-413.84	-259.34	-210.96	-156.73
Depreciation & Amortization	0.41	0.38	0.23	0.19	0.13
Stock-Based Compensation	55.72	49.49	41.12	32.3	34.24
Other Adjustments	0.1	0.13	1.13	1.13	1.11
Change in Receivables	0.99	3.23	-4.58	11.76	-11.63
Changes in Accounts Payable	-10.25	10.68	5.78	-17.12	16.25
Changes in Accrued Expenses	45	8.92	1.35	15.57	9.47
Changes in Income Taxes Payable	-2.39	-0.26	0.02	0.46	-0.09
Changes in Other Operating Activities	8.72	-34.61	0.06	-21.52	1.13
Operating Cash Flow	-407.31	-375.87	-214.23	-188.19	-106.11
Capital Expenditures	-0.01	-0.76	-0.36	-0.2	-0.25
Investing Cash Flow	-0.01	-0.76	-0.36	-0.2	-0.25
Issuance of Common Stock	596.26	454.81	478.44	71.16	200.13
Net Common Stock Issued (Repurchased)	596.26	454.81	478.44	71.16	200.13
Other Financing Activities	-0.5	-0.32	-6.01	-0.27	-
Financing Cash Flow	595.76	454.49	472.43	70.89	200.13
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.3	0.75	0.99	0.22	-0.09
Net Cash Flow	188.14	78.61	258.83	-117.29	93.67
Free Cash Flow	-407.32	-376.63	-214.59	-188.39	-106.37
Free Cash Flow Per Share	-2.23	-2.48	-1.55	-1.53	-0.97
Levered Free Cash Flow	-464.13	-429.49	-252.26	-233.58	-130.08
Unlevered Free Cash Flow	-491.65	-454.74	-276.25	-240.91	-129.3

Updated May 20, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q